AQDOT – Follow on Investment
We have recently made a follow-on investment into AQDOT on behalf of the University of Cambridge Enterprise Fund II and the Parkwalk UK Technology Fund V. AQDOT‘s technology allows for an energy- and raw material-efficient way of manufacturing… Read More
Horizon Discovery – Interim Results
Interim Results in-line and Panmure reaffirms ‘Buy Rating’: Interim Results for the Six Months Ended 30 June 2014 Horizon Reports a Strong First Half Positioning the Company for Continued Growth Cambridge, UK, 23 September 2014: Horizon Discovery Group… Read More
DefiniGEN Joins EBiSC Consortium
DefiniGEN (an investment in the University of Cambridge Enterprise Funds I & II), a leading provider of stem cell life science products and services has joined the European Bank for induced pluripotent stem cells (EBiSC) consortium. The consortium… Read More
RoadMap – University of Cambridge Enterprise Fund II investment
We have recently made an investment in RoadMap for the University of Cambridge Enterprise Fund II in a first round of financing of £515k. It is envisioned that a further financing round will be required in 12 months…. Read More
Jukedeck – University of Cambridge Enterprise Fund II investment
We have closed an investment in Jukedeck for the University of Cambridge Enterprise Fund II. Jukedeck provides unique, copyright-free music at the touch of a button. The product is based on a program that generates unique music algorithmically, built on three… Read More
Vocal IQ – University of Cambridge Enterprise Fund II investment
We have closed an investment, in a seed financing round of £750,000 in VocalIQ for the University of Cambridge Enterprise Fund II. The round was led by Amadeus Capital Partners. Cambridge Enterprise, the commercialisation arm of the University of Cambridge, is also investing…. Read More
Horizon Discovery – wins European Mediscience’s Emerging Star Award 2014
Horizon Discovery Group plc, the international life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, is delighted to announce that it has won the “Emerging Star” category at last… Read More
Sphere Fluidics – Parkwalk closes further funding round
We have closed an investment, in the first tranche of a financing round of up to £2m, in Sphere Fluidics for the University of Cambridge Enterprise Fund II and the final investment for Parkwalk Fund IV. This follows the UoCEF I… Read More
CCMOSS – Parkwalk closes further funding round
We have recently made an investment in Cambridge CMOS Sensors for the UK Tech Fund V and a Parkwalk Syndicate. This follows predecessor funds investing in 2012 and 2013. Cambridge CMOS Sensors are a leading manufacturer of sensor solutions… Read More
Horizon Discovery Says It Has Continued To Trade Strongly Since IPO
Horizon Discovery Group PLC said Wednesday that it had continued to trade strongly since its initial public offering. The company said it had traded “at least in line with expectations”, and that it is pursuing its strategy to… Read More
Horizon Discovery – Record AIM $113m IPO
Parkwalk portfolio company Horizon Discovery is set to create UK stock market history with a significantly oversubscribed AIM IPO on Thursday March 27, with a market cap of £120.5 million after raising £68.6m from institutional investors against an original target… Read More
Horizon – Intention to float on AIM
Horizon Discovery Group plc Announces Intention to Float THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED… Read More
Cambridge Enterprise
A huge thank you to all the team at Cambridge Enterprise for an excellent University of Cambridge Enterprise Fund investor evening yesterday at Emmanuel College. Investee companies presenting included: Aqdot (highlighted in the FT yesterday) Cambridge CMOS Sensors DefiniGEN… Read More
Horizon Discovery
Appointment of Chairman – Horizon Discovery has appointed Dr. Ian Gilham as Chairman of its Board of Directors. Dr. Gilham’s healthcare industry career spans thirty years encompassing all aspects of successful company growth and development. He was Chief Executive… Read More
Horizon Discovery
Horizon Discovery Signs Large-Scale License Agreement for its X-MAN Cell Lines in Japan Agreement covers use of 250 of Horizon’s X-MAN genetically defined isogenic cell lines Cambridge, UK, 30 January 2014: Horizon Discovery™ (Horizon), a leading provider of research… Read More
Horizon Discovery
Jan 7 (Reuters) – Horizon Discovery: * Horizon discovery and Astrazeneca have entered into a research, collaboration and license agreement * Agreement to explore a range of oncology-relevant genotypes * Will receive an undisclosed upfront payment * Eligible… Read More
DefiniGEN
Parkwalk closes DefiniGEN investment for the University of Cambridge Enterprise Fund II DefiniGEN provides human liver cells for preclinical drug development and disease modelling applications using human Induced Pluripotent Stem Cell hIPSC technology. The Company provides human cells… Read More
Horizon Discovery
Horizon Discovery named in the Deloitte Tech Fast 50 2013
Another Record year for University of Cambridge spin-out investments
The University of Cambridge has broken its early stage investment record for a second year running, approving nine seed fund investments for a total of £2.7 million, an increase on the £2.3 million invested in 2012/13. “During the… Read More
Posted on September 10, 2014
Fund Managers Comments
Cambridge